Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Respir Res ; 22(1): 66, 2021 Feb 24.
Article in English | MEDLINE | ID: mdl-33627105

ABSTRACT

BACKGROUND: FIBRONET was an observational, multicentre, prospective cohort study investigating the baseline characteristics, clinical course of disease and use of antifibrotic treatment in Italian patients with idiopathic pulmonary fibrosis (IPF). METHODS: Patients aged ≥ 40 years diagnosed with IPF within the previous 3 months at 20 Italian centres were consecutively enrolled and followed up for 12 months, with evaluations at 3, 6, 9 and 12 months. The primary objective was to describe the clinical course of IPF over 12 months of follow-up, including changes in lung function measured by % predicted forced vital capacity (FVC% predicted). RESULTS: 209 patients (82.3% male, mean age 69.54 ± 7.43 years) were enrolled. Mean FVC% predicted was relatively preserved at baseline (80.01%). The mean time between IPF diagnosis and initiation of antifibrotic therapy was 6.38 weeks; 72.3% of patients received antifibrotic therapy within the first 3 months of follow-up, and 83.9% within 12 months of follow-up. Mean FVC% predicted was 80.0% at baseline and 82.2% at 12 months, and 47.4% of patients remained stable (i.e. had no disease progression) in terms of FVC% predicted during the study. CONCLUSIONS: FIBRONET is the first prospective, real-life, observational study of patients with IPF in Italy. The short time between diagnosis and initiation of antifibrotic therapy, and the stable lung function between baseline and 12 months, suggest that early diagnosis and prompt initiation of antifibrotic therapy may preserve lung function in patients with IPF. TRIAL REGISTRATION: NCT02803580.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Idiopathic Pulmonary Fibrosis/physiopathology , Vital Capacity/physiology , Aged , Disease Progression , Female , Follow-Up Studies , Humans , Idiopathic Pulmonary Fibrosis/drug therapy , Male , Prognosis , Prospective Studies , Time Factors
2.
Sci Adv ; 5(12): eaay2670, 2019 12.
Article in English | MEDLINE | ID: mdl-31897430

ABSTRACT

The cellular and the molecular mechanisms by which long noncoding RNAs (lncRNAs) may regulate presynaptic function and neuronal activity are largely unexplored. Here, we established an integrated screening strategy to discover lncRNAs implicated in neurotransmitter and synaptic vesicle release. With this approach, we identified neuroLNC, a neuron-specific nuclear lncRNA conserved from rodents to humans. NeuroLNC is tuned by synaptic activity and influences several other essential aspects of neuronal development including calcium influx, neuritogenesis, and neuronal migration in vivo. We defined the molecular interactors of neuroLNC in detail using chromatin isolation by RNA purification, RNA interactome analysis, and protein mass spectrometry. We found that the effects of neuroLNC on synaptic vesicle release require interaction with the RNA-binding protein TDP-43 (TAR DNA binding protein-43) and the selective stabilization of mRNAs encoding for presynaptic proteins. These results provide the first proof of an lncRNA that orchestrates neuronal excitability by influencing presynaptic function.


Subject(s)
DNA-Binding Proteins/metabolism , RNA, Long Noncoding/metabolism , Synaptic Vesicles/metabolism , Animals , Cell Movement/genetics , DNA-Binding Proteins/genetics , HEK293 Cells , Hippocampus/cytology , Humans , Mice , Mice, Transgenic , Neurogenesis/genetics , Neurons/metabolism , Neurotransmitter Agents/metabolism , RNA, Messenger/metabolism , Rats , Rats, Wistar , Transfection
3.
Acta Physiol (Oxf) ; 221(1): 59-73, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28218996

ABSTRACT

AIM: Traffic between the plasma membrane and the endomembrane compartments is an essential feature of eukaryotic cells. The secretory pathway sends cargoes from biosynthetic compartments to the plasma membrane. This is counterbalanced by a retrograde endocytic route and is essential for cell homoeostasis. Cells need to adapt rapidly to environmental challenges such as the reduction of pO2 which, however, has not been analysed in relation to membrane trafficking in detail. Therefore, we determined changes in the plasma membrane trafficking in normoxia, hypoxia, and after reoxygenation. METHODS: Membrane trafficking was analysed by using the bulk membrane endocytosis marker FM 1-43, the newly developed membrane probe mCLING, wheat germ agglutinin as well as fluorescently labelled cholera toxin subunit B. Additionally, the uptake of specific membrane proteins was determined. In parallel, a non-biased SILAC screen was performed to analyse the abundance of membrane proteins in normoxia and hypoxia. RESULTS: Membrane trafficking was increased in hypoxia and quickly reversed upon reoxygenation. This effect was independent of the hypoxia-inducible factor (HIF) system. Using SILAC technology, we identified that the actin-bundling protein T-plastin is recruited to the plasma membrane in hypoxia. By the use of T-plastin knockdown cells, we could show that T-plastin mediates the hypoxia-induced membrane trafficking, which was associated with an increased actin density in the cells as determined by electron microscopy. CONCLUSION: Membrane trafficking is highly dynamic upon hypoxia. This phenotype is quickly reversible upon reoxygenation, which suggests that this mechanism participates in the cellular adaptation to hypoxia.


Subject(s)
Cell Membrane/metabolism , Hypoxia/metabolism , Membrane Glycoproteins/metabolism , Microfilament Proteins/metabolism , Protein Transport/physiology , Animals , Cell Line , Humans , Rats
4.
Mol Psychiatry ; 21(12): 1752-1767, 2016 12.
Article in English | MEDLINE | ID: mdl-26809838

ABSTRACT

Recombinant human erythropoietin (EPO) improves cognitive performance in neuropsychiatric diseases ranging from schizophrenia and multiple sclerosis to major depression and bipolar disease. This consistent EPO effect on cognition is independent of its role in hematopoiesis. The cellular mechanisms of action in brain, however, have remained unclear. Here we studied healthy young mice and observed that 3-week EPO administration was associated with an increased number of pyramidal neurons and oligodendrocytes in the hippocampus of ~20%. Under constant cognitive challenge, neuron numbers remained elevated until >6 months of age. Surprisingly, this increase occurred in absence of altered cell proliferation or apoptosis. After feeding a 15N-leucine diet, we used nanoscopic secondary ion mass spectrometry, and found that in EPO-treated mice, an equivalent number of neurons was defined by elevated 15N-leucine incorporation. In EPO-treated NG2-Cre-ERT2 mice, we confirmed enhanced differentiation of preexisting oligodendrocyte precursors in the absence of elevated DNA synthesis. A corresponding analysis of the neuronal lineage awaits the identification of suitable neuronal markers. In cultured neurospheres, EPO reduced Sox9 and stimulated miR124, associated with advanced neuronal differentiation. We are discussing a resulting working model in which EPO drives the differentiation of non-dividing precursors in both (NG2+) oligodendroglial and neuronal lineages. As endogenous EPO expression is induced by brain injury, such a mechanism of adult neurogenesis may be relevant for central nervous system regeneration.


Subject(s)
Erythropoietin/metabolism , Neurogenesis/drug effects , Oligodendroglia/drug effects , Animals , Brain/metabolism , Cell Differentiation/drug effects , Cell Differentiation/physiology , Central Nervous System/metabolism , Cognition/drug effects , Hippocampus/metabolism , Hippocampus/physiology , Male , Mice , Mice, Inbred C57BL , Neurogenesis/physiology , Neurons/metabolism , Oligodendroglia/metabolism , Pyramidal Cells/drug effects , Pyramidal Cells/metabolism , Recombinant Proteins/metabolism
6.
Neurol Sci ; 34(11): 2015-22, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23728715

ABSTRACT

Information about patients' adherence to therapy represents a primary issue in Parkinson's disease (PD) management. To perform the linguistic validation of the Italian version of the self-rated 8-Item Morisky Medical Adherence Scale (MMAS-8) and to describe in a sample of Italian patients affected by PD the adherence to anti-Parkinson drug therapy and the association between adherence and some socio-demographic and clinical features. MMAS-8 was translated into Italian language by two independent Italian mother-tongue translators. The consensus version was then back-translated by an English mother-tongue translator. This translation process was followed by a consensus meeting between the authors of translation and investigators and then by two comprehension tests. The translated version of the MMAS-8 scale was then administered at the baseline visit of the "REASON" study (Italian Study on the Therapy Management in Parkinson's disease: Motor, Non-Motor, Adherence and Quality Of Life Factors) in a large sample of PD patients. The final version of the MMAS-8 was easily understood. Mean ± SD MMAS-8 score was 6.1 ± 1.2. There were no differences in adherence to therapy in relationship to disease severity, gender, educational level or decision to change therapy. The Italian version of MMAS-8, the key tool of the REASON study to assess the adherence to therapy, has shown to be understandable to patients with PD. Patients enrolled in the REASON study showed medium therapy adherence.


Subject(s)
Antiparkinson Agents/administration & dosage , Medication Adherence , Parkinson Disease/drug therapy , Surveys and Questionnaires , Aged , Antiparkinson Agents/therapeutic use , Female , Humans , Male , Translations
7.
J Physiol ; 557(Pt 1): 77-91, 2004 May 15.
Article in English | MEDLINE | ID: mdl-15004214

ABSTRACT

Phosphoinositides are key regulators of synaptic vesicle cycling and endocytic traffic; the actin cytoskeleton also seems to be involved in modulating these processes. We investigated the effects of perturbing phosphoinositide signalling and actin dynamics on vesicle cycling in frog motor nerve terminals, using fluorescence and electron microscopy, and electrophysiology. Antibody staining for beta-actin revealed that actin surrounds but does not overlap with synaptic vesicle clusters. Latrunculin A, which disrupts actin filaments by binding actin monomers, and wortmannin, an inhibitor of phosphatidyl inositol-3-kinase (PI3-kinase), each disrupted the pattern of presynaptic actin staining, but not vesicle clusters in resting terminals. Latrunculin A, but not wortmannin, also reduced vesicle mobilization and exocytosis. Both drugs inhibited the stimulation-induced uptake of the styryl dye FM1-43 and blocked vesicle reformation from internalized membrane objects after tetanic stimulation. These results are consistent with a role of PI3-kinase and the actin cytoskeleton in the slow pathway of vesicle endocytosis, used primarily by reserve pool vesicles.


Subject(s)
Androstadienes/pharmacology , Bridged Bicyclo Compounds, Heterocyclic/pharmacology , Endocytosis/drug effects , Enzyme Inhibitors/pharmacology , Neuromuscular Junction/drug effects , Thiazoles/pharmacology , Acetylcholine/metabolism , Actins/drug effects , Actins/metabolism , Animals , Cytoskeleton/drug effects , Electrophysiology , Exocytosis/drug effects , Fluorescent Dyes , Guinea Pigs , In Vitro Techniques , Membrane Potentials/physiology , Microelectrodes , Microscopy, Electron , Microscopy, Fluorescence , Motor Endplate/drug effects , Motor Endplate/ultrastructure , Neuromuscular Junction/ultrastructure , Phosphoinositide-3 Kinase Inhibitors , Presynaptic Terminals/drug effects , Rana pipiens , Signal Transduction/drug effects , Thiazolidines , Wortmannin
8.
Neurobiol Dis ; 8(6): 1069-81, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11741402

ABSTRACT

Biochemical and immunological studies have shown that mice infected with LP-BM5 virus develop antibodies to ionotropic glutamate receptors. Here, IgG isolated from brain of infected mice has been tested electrophysiologically on cultured rat cortical and hippocampal neurons. The IgG elicited glycine-independent currents that reversed at approximately 0 mV. Equivalent concentrations of IgG from uninfected mice were inactive. The glycine-independent currents were less influenced by DNQX and GYKI-52466 than currents elicited by AMPA and KA. The IgG also elicited glycine-dependent currents that reversed at -10 mV and were blocked by dl-AP5, 5,7-DCKA, and polyamine amides. Glycine-dependent and -independent currents were unaffected by tetrodotoxin, strychnine, the transmembrane Cl- gradient or d-tubocurare. Although part of the glycine-independent current remains uncharacterized, these results confirm that a virus-induced immunopathology produces IgG clones that activate ionotropic glutamate receptors and that could, thereby, contribute to the excitotoxic neurological syndrome observed in LP-BM5-infected mice.


Subject(s)
Autoantibodies/immunology , Autoimmune Diseases of the Nervous System/immunology , Brain/immunology , Immunoglobulin G/immunology , Murine pneumonia virus/immunology , Neurodegenerative Diseases/immunology , Neurons/immunology , Receptors, Glutamate/immunology , Animals , Autoantibodies/metabolism , Autoantibodies/pharmacology , Autoimmune Diseases of the Nervous System/physiopathology , Autoimmune Diseases of the Nervous System/virology , Brain/drug effects , Brain/virology , Cells, Cultured , Cerebral Cortex/drug effects , Cerebral Cortex/immunology , Cerebral Cortex/virology , Disease Models, Animal , Dose-Response Relationship, Drug , Excitatory Amino Acid Agonists/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Fetus , Glycine/pharmacology , Hippocampus/drug effects , Hippocampus/immunology , Hippocampus/virology , Immunoglobulin G/metabolism , Immunoglobulin G/pharmacology , Membrane Potentials/drug effects , Membrane Potentials/physiology , Murine pneumonia virus/pathogenicity , Neurodegenerative Diseases/physiopathology , Neurodegenerative Diseases/virology , Neurons/drug effects , Neurons/virology , Nicotinic Antagonists/pharmacology , Pyramidal Cells/drug effects , Pyramidal Cells/immunology , Pyramidal Cells/virology , Rats , Rats, Wistar , Receptors, AMPA/drug effects , Receptors, AMPA/immunology , Receptors, AMPA/metabolism , Receptors, Glutamate/drug effects , Receptors, Glutamate/metabolism , Receptors, N-Methyl-D-Aspartate/drug effects , Receptors, N-Methyl-D-Aspartate/immunology , Receptors, N-Methyl-D-Aspartate/metabolism , Tubocurarine/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...